Autoantibody
Introduction
Autoantibodies are a class of antibodies produced by the immune system that mistakenly target and react with the body's own proteins, cells, or tissues. Normally, the immune system distinguishes between "self" and "non-self" components, producing antibodies to neutralize foreign invaders like bacteria and viruses. However, in cases of autoimmunity, this self-tolerance breaks down, leading to the production of autoantibodies. The interaction of antibodies with their targets, and how this interaction can be influenced by genetic variations, is an area of active research. For instance, some non-synonymous single nucleotide polymorphisms (nsSNPs) have been observed to alter antibody binding affinity, which can impact the measurement and function of protein levels. [1]
Biological Basis
The immune system's ability to recognize and respond to foreign pathogens while tolerating the body's own components is crucial. This self-tolerance is primarily maintained through complex mechanisms involving T cells and B cells. When these mechanisms fail, B cells may produce autoantibodies. The specific triggers for this loss of tolerance are diverse and can include genetic predisposition, environmental factors like infections, and exposure to certain chemicals. The presence of specific autoantibodies often correlates with various inflammatory processes, which involve cytokines like TNF-alpha and interleukin-6 (IL-6). [1]
Clinical Relevance
Autoantibodies are central to the pathology and diagnosis of a wide range of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, and autoimmune thyroid disorders. Their detection in blood samples serves as crucial diagnostic markers, helping clinicians identify and classify autoimmune conditions. For example, elevated levels of certain inflammatory markers, which can be influenced by genetic variations, are often observed in autoimmune diseases. [1] Understanding the genetic factors influencing protein levels and immune responses, such as those related to ABO blood groups and TNF-alpha levels, can provide insights into disease mechanisms. [1]
Social Importance
Autoimmune diseases, characterized by the presence of autoantibodies, represent a significant global health burden, affecting millions of individuals and often leading to chronic conditions, disability, and reduced quality of life. Research into autoantibodies and their genetic underpinnings is vital for developing improved diagnostic tools, targeted therapies, and ultimately, preventative strategies. Advances in genomics, such as genome-wide association studies (GWAS), contribute to identifying genetic loci associated with various biomarker traits, including those relevant to immune function and inflammation. [1] This research enhances our understanding of disease mechanisms and paves the way for personalized medicine approaches.
Methodological and Statistical Considerations
Many genome-wide association studies (GWAS) are conducted using moderate-sized cohorts, which can inherently limit the statistical power to reliably detect genetic variants with small effect sizes, potentially leading to an overestimation of effects for initially identified associations. [2] While meta-analyses help increase power by aggregating data, the ultimate success in discovering novel genetic loci remains contingent on achieving sufficiently large sample sizes and comprehensive SNP coverage. [3] Current GWAS, often relying on a subset of available SNPs (e.g., from HapMap), may miss causal variants or genes due to incomplete genomic coverage, hindering a comprehensive understanding of candidate gene regions. [4]
Furthermore, the replication of genetic findings presents challenges; while some studies show high replication rates, others encounter non-replication at the single nucleotide polymorphism (SNP) level. This discrepancy can arise if different studies identify distinct SNPs that are in strong linkage disequilibrium with the same underlying causal variant, or if multiple causal variants exist within a gene region. [2] The necessity for rigorous statistical corrections for multiple testing across the vast number of genomic variants tested can also lead to conservative significance thresholds, potentially obscuring real but modest genetic effects and sometimes requiring the application of alternative metrics like false discovery rates. [1]
Generalizability and Cohort Specificity
The generalizability of findings from specific study populations, such as cohorts composed of twins or self-selected volunteers, may not be directly applicable to the broader general population. [5] Although studies may find no evidence of phenotypic differences for the traits examined between twins and non-twins in relevant age groups, the voluntary nature of participation can introduce selection biases that might affect the representativeness of the sample. [5] Similarly, investigations conducted in founder populations, while offering advantages for certain genetic analyses, may not fully capture the genetic diversity and variant frequencies present in more heterogeneous populations, thereby limiting the direct transferability of identified associations across diverse ancestries. [2]
Phenotypic Characterization and Biological Interpretation
Accurate phenotypic characterization is crucial, but several factors can complicate the interpretation of associations between genetic variants and trait levels. For instance, the choice of tissue for gene expression analysis may not always be the most biologically relevant for accurately reflecting circulating protein levels, particularly for complex traits or those involving dynamic biological processes like inflammatory responses. [1] Additionally, certain genetic variants, such as non-synonymous SNPs, could potentially alter the binding affinity of antibodies used in protein measurement assays, which might lead to spurious associations or misinterpretations of actual protein concentrations. [1] Addressing these potential measurement biases and confirming the precise biological mechanisms often necessitates extensive re-sequencing efforts or detailed functional studies. [1]
Unaccounted Factors and Remaining Knowledge Gaps
Despite the significant advancements offered by GWAS in identifying genetic associations, the intricate interplay between genetic predispositions and environmental factors is frequently not fully elucidated. Beyond identified genetic variants, numerous other biological and environmental processes can influence protein levels and complex phenotypes, representing potential confounders that remain largely uncharacterized. [1] This contributes to the phenomenon of "missing heritability" and leaves substantial knowledge gaps regarding the complete etiology of complex traits. A fundamental challenge remains in identifying and prioritizing associated SNPs for subsequent functional validation, which requires ongoing research to delineate causal mechanisms and explore additional biomarker phenotypes and variants. [6]
Variants
Genetic variations play a crucial role in individual differences in health and disease, particularly within the immune system and metabolic pathways. The region encompassing HLA-DRA and HLA-DRB9 contains rs9268813, a variant located within the Major Histocompatibility Complex (MHC) Class II genes. These genes are fundamental to the immune system, encoding proteins that present processed antigens to T-cells, thereby initiating targeted immune responses. Variants in this highly polymorphic region, including rs9268813, are frequently associated with susceptibility to a wide array of autoimmune diseases by influencing which antigens the immune system recognizes.. [1] Similarly, rs7528684 is located near FCRL3 (Fc Receptor Like 3), a gene encoding an immune receptor expressed on B lymphocytes that is important for B-cell development and function. Genetic variations in FCRL3 have been linked to altered immune regulation and an increased risk for autoimmune conditions, potentially affecting antibody production or immune cell signaling. The variant rs3184504 in SH2B3 (SH2B Adaptor Protein 3), an adaptor protein involved in cytokine signaling, is also a recognized risk factor for several autoimmune diseases, modulating inflammatory responses.. [6]
The ABO gene, represented by the variant rs657152, is responsible for determining the ABO blood group system through its glycosyltransferase enzymes. These enzymes add specific sugar residues to a precursor H antigen, with the A allele producing an alpha1,3 N-acetylgalactosaminyltransferase and the B allele producing an alpha1,3 galactosyltransferase, while the O allele results in an inactive enzyme.. [7] The SNP rs657152 within the ABO gene is significantly associated with plasma Alkaline Phosphatase (ALP) levels, explaining a notable portion of its total variance.. [8] This association may stem from genetically determined differences in the proportions of ALP isoenzymes in circulation, particularly intestinal ALP, which can vary with an individual's ABO blood group and secretor status.. [8]
Other genetic variants listed contribute to diverse biological functions across the human genome. For instance, rs28600853 is located in a region encompassing TTC34 (Tetratricopeptide Repeat Domain 34), involved in protein-protein interactions, and ACTRT2 (Actin Related Protein T2), a component of the cytoskeleton critical for cell shape and movement. The variant rs428595 is found near MIR130B (microRNA 130b), which regulates gene expression and influences various cellular processes, including inflammation, and PPIL2 (Peptidylprolyl Isomerase Like 2), an enzyme assisting in proper protein folding.. [1] Additionally, rs9934817 is located within RBFOX1 (RNA Binding Fox-1 Homolog 1), an RNA binding protein essential for alternative splicing, especially in neural development, thereby impacting protein diversity and cellular function. The variant rs3842727 is found in a region containing INS (Insulin), a key hormone for glucose regulation, and TH (Tyrosine Hydroxylase), the rate-limiting enzyme in neurotransmitter synthesis. These genes are crucial for metabolic health and neurological processes, respectively. Further variants such as rs6679677 (near PHTF1 and RSBN1) and rs11705721 (in PXK) exemplify the broad impact of common genetic variations on fundamental cellular mechanisms like membrane trafficking and protein sorting, which are vital for cell homeostasis.. [6]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs9268813 | HLA-DRA - HLA-DRB9 | atopic asthma asthma adult onset asthma myositis autoantibody measurement |
| rs657152 | ABO | alkaline phosphatase measurement, enzyme/coenzyme activity trait interleukin-6 measurement hormone measurement, thyroid stimulating hormone amount autoantibody measurement phytosterol measurement |
| rs28600853 | TTC34 - ACTRT2 | autoantibody measurement |
| rs7528684 | FCRL3 - VDAC1P9 | autoantibody measurement Fc receptor-like protein 3 measurement |
| rs428595 | MIR130B - PPIL2 | disease free survival, type 1 diabetes mellitus autoantibody measurement |
| rs9934817 | RBFOX1 | autoantibody measurement |
| rs3842727 | INS - TH | autoantibody measurement disease free survival, type 1 diabetes mellitus type 1 diabetes mellitus |
| rs3184504 | ATXN2, SH2B3 | beta-2 microglobulin measurement hemoglobin measurement lung carcinoma, estrogen-receptor negative breast cancer, ovarian endometrioid carcinoma, colorectal cancer, prostate carcinoma, ovarian serous carcinoma, breast carcinoma, ovarian carcinoma, squamous cell lung carcinoma, lung adenocarcinoma platelet crit coronary artery disease |
| rs6679677 | PHTF1 - RSBN1 | rheumatoid arthritis, celiac disease type 1 diabetes mellitus rheumatoid arthritis hypothyroidism keratinocyte carcinoma |
| rs11705721 | PXK | autoantibody measurement |
Causes
The development of autoantibodies, which signify a breakdown in immune tolerance and can lead to autoimmune conditions, is a complex process influenced by a combination of genetic predispositions, environmental exposures, and broader biological factors. Research indicates that various factors contribute to the immune dysregulation that can result in the production of antibodies targeting self-antigens.
Genetic Susceptibility and Immune Homeostasis
Genetic factors are fundamental in determining an individual's susceptibility to immune dysregulation and the subsequent production of autoantibodies. Genome-wide association studies (GWAS) have identified numerous common genetic variants that collectively contribute to the risk of complex diseases and influence key biomarker traits relevant to immune function. [9] These inherited variants, often acting in a polygenic manner, can alter the expression or function of genes involved in immune cell development, activation, and the critical mechanisms that maintain self-tolerance within the immune system.
Specific genetic loci have been linked to the regulation of immune mediators and proteins, providing insight into potential mechanisms. For example, variations near genes such as IL2RA, RBM17, FCER1A, and CRP have been associated with circulating levels of C-reactive protein (CRP) and interleukin-6 (IL-6), both potent inflammatory markers. [6] Similarly, genetic variations in CHI3L1 influence serum YKL-40 levels, a biomarker implicated in inflammatory and immune responses. [10] The ABO histo-blood group locus, which encodes glycosyltransferase enzymes determining blood antigens, also affects levels of soluble intercellular adhesion molecule-1 (ICAM1) and tumor necrosis factor-alpha (TNF-alpha), crucial molecules for immune cell communication and inflammation. [7] These genetic influences on protein quantitative trait loci (pQTLs) suggest that mechanisms such as differential enzyme activity, altered protein processing, or changes in receptor binding affinity can perturb the immune landscape, contributing to a predisposition for autoantibody generation. [1]
Environmental Modulators of Immune Response
Environmental factors serve as crucial external modulators that can either trigger or exacerbate immune dysregulation, potentially leading to the formation of autoantibodies. Lifestyle choices and dietary patterns significantly influence the body's metabolic state and overall inflammatory burden, thereby affecting an individual's susceptibility to various immune-related phenotypes. [11] Exposure to certain environmental agents, such as bacterial components like lipopolysaccharide, can robustly stimulate immune cells, leading to elevated levels of inflammatory cytokines, which can disrupt the delicate balance of immune tolerance. [1] These exogenous stimuli interact with an individual's biological systems, shaping the immune system's reactivity and its propensity to mount aberrant responses against self-antigens.
Interplay of Genes and Environment
The emergence of immune dysregulation and autoantibody production is frequently a result of intricate interactions between an individual's genetic predispositions and their environmental exposures. Genetically determined "metabotypes," which represent variations in metabolic profiles, have been shown to interact with environmental factors such as nutrition and lifestyle, influencing an individual's susceptibility to complex, multifactorial diseases. [11] This indicates that specific genetic vulnerabilities may only become manifest or exert their full effect when combined with particular environmental triggers. For instance, the association between the ABO blood group and TNF-alpha levels is most pronounced in individuals with the highest TNF-alpha concentrations, suggesting a context-dependent genetic effect that can be modulated by environmental or other physiological factors. [1] These gene-environment interactions underscore a dynamic process where inherited susceptibilities are either unveiled or intensified by external stimuli, ultimately contributing to a breakdown in immune tolerance.
Systemic Factors and Immune Dysregulation
Broader systemic physiological conditions and other biological factors play a significant role in the complex etiology of immune dysregulation. While specific comorbidities or medication effects directly causing autoantibodies are not extensively detailed, general inflammatory states, characterized by elevated C-reactive protein (CRP) and interleukin-6 (IL-6) levels, are commonly associated with various health conditions and can profoundly influence overall immune activity. [6] Additionally, age-related changes in the immune system, often referred to as immunosenescence, can alter immune cell function and regulatory mechanisms, potentially increasing the risk of developing autoimmune phenomena. The cumulative impact of these systemic factors can create an internal environment that is conducive to the loss of self-tolerance and the subsequent generation of autoantibodies.
Cellular and Molecular Foundations of Immune Responses
The immune system orchestrates complex cellular and molecular pathways to defend the body, often involving specialized cells like mast cells and macrophages. A key player in allergic responses is immunoglobulin E (IgE), an antibody that, upon binding to high-affinity receptors on mast cells and other immune cells, initiates a cascade of intracellular signaling events. This activation leads to the rapid release of various inflammatory mediators, including chemokines and cytokines, which recruit other immune cells and amplify the immune response. For instance, monomeric IgE can enhance human mast cell chemokine production, a process further augmented by IL-4 and suppressed by dexamethasone. [12]
Human alveolar macrophages, crucial immune cells found in the lungs, also become activated by IgE receptors, leading to the production of both proinflammatory and anti-inflammatory cytokines, as well as chemokines. [13] This intricate interplay of cellular functions and regulatory networks ensures a finely tuned immune response, although dysregulation can contribute to conditions like asthma. The high-affinity IgE receptor on mast cells, when weakly stimulated, preferentially signals for and induces allergy-promoting lymphokines [14] highlighting the sensitivity and specific outcomes of these molecular pathways.
Genetic Regulation of Immune Biomolecules
Genetic mechanisms play a significant role in shaping individual immune responses and the levels of critical immune biomolecules. A prime example is the ABO histo-blood group antigen, determined by variants at the ABO locus on chromosome 9q34.2. [7] The ABO gene encodes glycosyltransferase enzymes that transfer specific sugar residues to a precursor H antigen, with alleles like A, B, and O encoding enzymes with differing specificities and activities. [7] For instance, the A allele encodes alpha1R3 N-acetylgalactosamyl-transferase, forming the A antigen, while the O allele does not produce an active enzyme. [7]
Variations within the ABO locus, such as specific single nucleotide polymorphisms (SNPs), have been associated with altered levels of important inflammatory proteins. For example, the ABO blood group has been linked to TNF-alpha levels [1] and a common nonsynonymous polymorphism determining the B group and A allele (e.g., rs8176746, which changes a leucine to methionine) is one of the independent signals in the ABO gene associated with TNF-alpha levels. [1] Furthermore, the ABO histo-blood group antigen is novelly associated with soluble ICAM-1 levels, indicating a genetic influence on cell adhesion molecules that are vital for immune cell trafficking. [7] The ICAM1 locus itself, at 19p13.2, also shows strong association with soluble ICAM-1. [7]
Inflammatory Mediators and Their Systemic Impact
Key biomolecules like Monocyte Chemoattractant Protein-1 (MCP1), Tumor Necrosis Factor-alpha (TNF-alpha), and Interleukin-6 (IL6) are central to pathophysiological processes, including inflammation and homeostatic disruptions. MCP1, a chemokine, is stimulated by the high-affinity receptor for IgE and plays a role in recruiting monocytes to sites of inflammation. [15] Its synthesis can be activated by diisocyanate antigens in occupational asthma, suggesting its utility as a biomarker for disease identification. [16] Similarly, TNF-alpha and IL6 are potent proinflammatory cytokines that contribute to systemic inflammation and are implicated in various disease mechanisms.
Intercellular Adhesion Molecule-1 (ICAM-1), a critical structural component and receptor, facilitates the binding of immune cells like the integrin Mac-1 (CD11b/CD18) and is crucial for generating effector cells mediating inflammatory responses . [7], [17] Its signaling activity can be enhanced by sialylated complex-type N-glycans, as observed in mouse astrocytes [18] highlighting the importance of post-translational modifications. Disruptions in the regulation of these inflammatory mediators can lead to systemic consequences, such as an increased risk for vascular disease, where ABO blood group variations have also been noted to play a role . [19], [20]
Immune Cell Activation and Inflammatory Signaling
IgE receptor activation on mast cells and alveolar macrophages initiates intracellular signaling cascades, leading to the production of chemokines like monocyte chemoattractant protein-1 (MCP-1) and various pro- and anti-inflammatory cytokines. [13] This process involves the high-affinity IgE receptor (FcεRI), whose stimulation can induce allergy-promoting lymphokines. [14] The c-kit ligand, stem cell factor, and anti-IgE antibodies can further promote MCP-1 expression in human lung mast cells. [21] Furthermore, monomeric IgE enhances mast cell chemokine production, a response that can be augmented by IL-4 and suppressed by dexamethasone, illustrating complex feedback loops and regulatory interactions within these inflammatory pathways. [12]
Genetic and Post-Translational Regulatory Mechanisms
Genetic variants, such as single nucleotide polymorphisms (SNPs), play a critical role in regulating gene expression and protein levels, often identified through genome-wide association studies of expression quantitative trait loci (eQTLs) and protein quantitative trait loci (pQTLs). [22] These regulatory mechanisms extend to post-translational modifications, including alternative pre-mRNA splicing, which can profoundly alter protein function. For example, common SNPs in HMGCR have been shown to affect the alternative splicing of exon 13, influencing LDL-cholesterol levels. [23] Such precise control over gene and protein structure is fundamental to maintaining cellular homeostasis and can, when dysregulated, contribute to altered immune responses.
Metabolic Pathway Interplay with Immune Regulation
Metabolomics offers a comprehensive view of endogenous metabolites, providing a functional readout of the body's physiological state and revealing how genetic variants impact the homeostasis of key lipids, carbohydrates, or amino acids. [11] These metabolic profiles are intrinsically linked to immune function, as metabolic shifts can influence immune cell activation and inflammatory processes. For instance, Glutathione S-transferase omega 1 and omega 2 (GSTO1 and GSTO2) are involved in xenobiotic and oxidative stress metabolism, and their pharmacogenomics highlight the intricate link between metabolism and cellular responses. [24] Additionally, Carboxypeptidase N is recognized as a pleiotropic regulator of inflammation, demonstrating how specific metabolic enzymes can directly modulate immune-inflammatory pathways. [25]
Systems-Level Integration and Disease Mechanisms
The interplay between genetic predispositions, environmental factors, and molecular pathways results in complex phenotypes and disease susceptibility, often involving significant pathway crosstalk and network interactions. [11] Systemic inflammation, as observed in conditions like Chronic Obstructive Pulmonary Disease (COPD), illustrates how dysregulation across multiple integrated pathways contributes to disease pathogenesis. [26] In the context of autoantibodies, diseases such as Goodpasture's syndrome, characterized by immune responses against type IV collagen, exemplify how specific molecular targets and their associated pathways become dysregulated, leading to severe tissue damage. [27] Understanding these emergent properties from interconnected biological networks is crucial for identifying potential therapeutic targets and developing interventions for immune-mediated disorders.
There is no information about the clinical relevance of 'autoantibody' in the provided context.
References
[1] Melzer D, Perry JR, Hernandez D, et al. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genet, vol. 4, no. 5, 2008, p. e1000072.
[2] Sabatti, Chiara et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nature Genetics, vol. 40, no. 12, 2008, pp. 1392–1398. PMID: 19060910.
[3] Kathiresan, Sekar et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nature Genetics, vol. 40, no. 12, 2008, pp. 1421–1426. PMID: 19060906.
[4] Yang, Qiong et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Medical Genetics, vol. 8, 2007, p. 76. PMID: 17903294.
[5] Benyamin, Beben et al. "Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels." American Journal of Human Genetics, vol. 84, no. 1, 2009, pp. 60–65. PMID: 19084217.
[6] Benjamin EJ, Dupuis J, Larson MG, et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Med Genet, vol. 8, no. Suppl 1, 2007, p. S11.
[7] Pare G, Chasman DI, Parker AN, et al. "Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women." PLoS Genet, vol. 4, no. 7, 2008, p. e1000118.
[8] Yuan, Xin et al. "Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes." American Journal of Human Genetics, vol. 83, no. 5, 2008, pp. 520–528. PMID: 18940312.
[9] Lohmueller, Katherine E., et al. "Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease." Nature Genetics, vol. 33, no. 2, 2003, pp. 177-182.
[10] Ober, Carole, et al. "Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function." New England Journal of Medicine, vol. 358, no. 16, 2008, pp. 1682-1691.
[11] Gieger, C., et al. "Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum." PLoS Genetics, vol. 4, no. 11, 2008, e1000282.
[12] Matsuda, K., et al. "Monomeric IgE enhances human mast cell chemokine production: IL-4 augments and dexamethasone suppresses the response." Journal of Allergy and Clinical Immunology, vol. 116, 2005, pp. 1357-1363.
[13] Gosset, P., et al. "Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors." Journal of Allergy and Clinical Immunology, vol. 103, 1999, pp. 289-297.
[14] Gonzalez-Espinosa, C., et al. "Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells." Journal of Experimental Medicine, vol. 197, 2003, pp. 1453-1465.
[15] Eglite, S., et al. "Synthesis and Secretion of Monocyte Chemotactic Protein-1 Stimulated by the High Affinity Receptor for IgE." Journal of Immunology, vol. 170, no. 5, 2003, pp. 2680-2687.
[16] Bernstein, D. I., et al. "Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma." American Journal of Respiratory and Critical Care Medicine, vol. 166, 2002, pp. 445-450.
[17] Diamond, M. S., et al. "Binding of the Integrin Mac-1 (CD11b/CD18) to the Third Immunoglobulin-Like Domain of ICAM-1 (CD54) and Its Regulation by Glycosylation." Cell, vol. 65, no. 6, 1991, pp. 961-971.
[18] Otto, V. I., et al. "Sialylated Complex-Type N-Glycans Enhance the Signaling Activity of Soluble Intercellular Adhesion Molecule-1 in Mouse Astrocytes." Journal of Biological Chemistry, vol. 279, no. 34, 2004, pp. 35201-35209.
[19] Platt, D., et al. "ABO Blood Group System, Age, Sex, Risk Factors and Cardiac Infarction." Archiv für Gerontologie und Geriatrie, vol. 4, no. 4, 1985, pp. 309-322.
[20] Medalie, J. H., et al. "Blood Groups, Myocardial Infarction and Angina Pectoris Among 10,000 Adult Males." New England Journal of Medicine, vol. 285, no. 24, 1971, pp. 1348-1353.
[21] Baghestanian, M., et al. "The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells." Blood, vol. 90, 1997, pp. 4438-4449.
[22] Goring, H. H., et al. "Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes." Nature Genetics, vol. 10, 2007, pp. 1208–1216.
[23] Burkhardt, R., et al. "Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, 2008, pp. 2076-2081.
[24] Mukherjee, B., et al. "Glutathione S-transferase omega 1 and omega 2 pharmacogenomics." Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 34, no. 7, 2006, pp. 1237-1246.
[25] Matthews, K. W., Mueller-Ortiz, S. L., and Wetsel, R. A. "Carboxypeptidase N: A pleiotropic regulator of inflammation." Molecular Immunology, vol. 40, 2004, pp. 785–793.
[26] Walter, R. E., et al. "Systemic inflammation and COPD: The Framingham Heart Study." Chest, in press.
[27] Wilk, J. B., et al. "Framingham Heart Study genome-wide association: results for pulmonary function measures." BMC Medical Genetics, vol. 8, 2007, p. S12.